When Bad Data Enters the Drug Pipeline - Takeaways - MDSpire

When Bad Data Enters the Drug Pipeline

Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.

  • By

  • Kathryn Wighton

  • June 11, 2026

  • 2 min

Share

  • 1

    Jaynier Moya, MD, and three coordinators face charges for allegedly falsifying data in drug trials at Pines Care Research Center.

  • 2

    The alleged misconduct reportedly began no later than 2019, involving false records of participant medication and testing.

  • 3

    Prosecutors claim identification documents from non-participants were used to create fraudulent participant records.

  • 4

    Falsified data was allegedly submitted into clinical trial databases, impacting evaluations of new drugs.

  • 5

    The case highlights the importance of data integrity in clinical trials for regulatory evaluations and public confidence.

Original Source(s)

When Bad Data Enters the Drug Pipeline

  • by Kathryn Wighton

  • June 11, 2026

Related Content

Aid in Dying Nears One Third of US

New laws in New York and Illinois will soon make medical aid in dying available to nearly one-third of Americans.

Trump Bought Tobacco Stocks and Raked In Industry Donations as FDA Eased Standards

Trump’s tobacco investments and industry donations coincided with FDA moves that benefited major nicotine companies.

Efficacy and safety of transcatheter left atrial appendage closure guided by transoesophageal echocardiography using standard and micro TEE probes: a single-center retrospective study